Dr. Rachel Sanborn, MD
Claim this profileProvidence Portland Medical Center
Expert in Non-Small Cell Lung Cancer
Expert in Cancer
42 reported clinical trials
67 drugs studied
About Rachel Sanborn, MD
Education:
- MD (Doctor of Medicine) from Oregon Health & Science University, completed in 2005.
Experience:
- Medical Oncologist at Providence Cancer Institute.
- Currently the Medical Director of the Gastrointestinal Oncology Program.
- Associate Professor of Medicine at Oregon Health & Science University.
- Actively involved in clinical research with numerous publications in peer-reviewed journals.
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
metastatic
2Cancer
Global LeaderStage IV
Stage III
metastatic
Affiliated Hospitals
Clinical Trials Rachel Sanborn, MD is currently running
Zipalertinib
for Non-Small Cell Lung Cancer
This trial is testing CLN-081, a new drug, in patients with a specific type of lung cancer that has a genetic mutation. The drug aims to block a protein that helps cancer cells grow, to see if it can slow down or stop the cancer.
Recruiting1 award Phase 1 & 23 criteria
TROP2 ADC
for Cancer
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Small cell lung cancer 6. HR+/ HER2-breast cancer 7. Head and neck squamous cell carcinoma 8. Endometrial carcinoma 9. Urothelial carcinoma
Recruiting1 award Phase 1 & 213 criteria
More about Rachel Sanborn, MD
Clinical Trial Related4 years of experience running clinical trials · Led 42 trials as a Principal Investigator · 15 Active Clinical TrialsTreatments Rachel Sanborn, MD has experience with
- Pembrolizumab
- Nivolumab
- Pemetrexed
- Ipilimumab
- Carboplatin
- Atezolizumab
Breakdown of trials Rachel Sanborn, MD has run
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rachel Sanborn, MD specialize in?
Rachel Sanborn, MD focuses on Non-Small Cell Lung Cancer and Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Rachel Sanborn, MD currently recruiting for clinical trials?
Yes, Rachel Sanborn, MD is currently recruiting for 15 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Rachel Sanborn, MD has studied deeply?
Yes, Rachel Sanborn, MD has studied treatments such as Pembrolizumab, Nivolumab, Pemetrexed.
What is the best way to schedule an appointment with Rachel Sanborn, MD?
Apply for one of the trials that Rachel Sanborn, MD is conducting.
What is the office address of Rachel Sanborn, MD?
The office of Rachel Sanborn, MD is located at: Providence Portland Medical Center, Portland, Oregon 97213 United States. This is the address for their practice at the Providence Portland Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.